Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$326.09 +1.0%	$288.10	$205.87 ▼ $330.16	$42.09B	0.22	859,514 shs	943,507 shs
BMRN BioMarin Pharmaceutical	$54.97 -0.4%	$58.39	$52.93 ▼ $94.85	$10.58B	0.19	1.72 million shs	1.56 million shs
GLPG Galapagos	$27.99 +0.0%	$27.63	$22.36 ▼ $31.23	N/A	0.07	251,125 shs	133,978 shs
GNMSF Genmab A/S	$211.09	$207.95	$170.00 ▼ $292.80	$13.95B	0.92	240 shs	N/A
TEVA Teva Pharmaceutical Industries	$16.76	$16.79	$12.47 ▼ $22.80	$19.22B	0.6	10.28 million shs	7.56 million shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	0.00%	+4.24%	+5.99%	+19.56%	+32.85%
BMRN BioMarin Pharmaceutical	0.00%	+0.31%	-4.86%	-21.96%	-32.99%
GLPG Galapagos	0.00%	+2.04%	-3.58%	+11.39%	+12.91%
GNMSF Genmab A/S	0.00%	0.00%	+1.61%	+11.22%	-14.01%
TEVA Teva Pharmaceutical Industries	0.00%	-1.25%	-0.09%	+8.90%	+3.11%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALNY Alnylam Pharmaceuticals	4.2538 of 5 stars	2.4	4.0	4.3	3.9	2.5	0.6
BMRN BioMarin Pharmaceutical	4.9096 of 5 stars	3.4	3.0	3.3	3.3	2.5	3.8
GLPG Galapagos	0.3642 of 5 stars	0.8	3.0	0.0	1.9	0.0	0.6
GNMSF Genmab A/S	0.3162 of 5 stars	0.0	3.0	0.0	0.0	0.0	1.3
TEVA Teva Pharmaceutical Industries	4.016 of 5 stars	4.6	3.0	0.0	2.0	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.79	Moderate Buy	$340.00	4.27% Upside
BMRN BioMarin Pharmaceutical	2.74	Moderate Buy	$93.45	70.01% Upside
GLPG Galapagos	1.50	Reduce	$25.33	-9.49% Downside
GNMSF Genmab A/S	0.00	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	3.22	Buy	$24.13	43.94% Upside

Current Analyst Ratings Breakdown

Latest GNMSF, ALNY, GLPG, BMRN, and TEVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	ALNY Alnylam Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$287.00 ➝ $333.00
6/26/2025	ALNY Alnylam Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$320.00 ➝ $377.00
6/26/2025	TEVA Teva Pharmaceutical Industries	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $23.00
6/24/2025	ALNY Alnylam Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$300.00 ➝ $360.00
6/12/2025	ALNY Alnylam Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$330.00 ➝ $338.00
6/6/2025	TEVA Teva Pharmaceutical Industries	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$24.00
5/28/2025	TEVA Teva Pharmaceutical Industries	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00
5/27/2025	TEVA Teva Pharmaceutical Industries	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/12/2025	TEVA Teva Pharmaceutical Industries	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$21.00 ➝ $23.00
5/8/2025	TEVA Teva Pharmaceutical Industries	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $22.00
5/5/2025	BMRN BioMarin Pharmaceutical	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$124.00 ➝ $104.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$2.25B	18.91	N/A	N/A	$0.52 per share	627.10
BMRN BioMarin Pharmaceutical	$2.85B	3.69	$3.23 per share	17.00	$29.69 per share	1.85
GLPG Galapagos	$298.31M	N/A	$0.73 per share	38.54	$47.57 per share	N/A
GNMSF Genmab A/S	$3.12B	4.47	$15.19 per share	13.90	$80.53 per share	2.62
TEVA Teva Pharmaceutical Industries	$16.54B	1.16	$3.37 per share	4.98	$4.74 per share	3.54

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	-$278.16M	-$2.09	N/A	366.39	N/A	-11.49%	-510.31%	-6.48%	7/30/2025 (Estimated)
BMRN BioMarin Pharmaceutical	$426.86M	$2.69	20.44	12.61	0.76	17.76%	11.34%	8.95%	8/4/2025 (Estimated)
GLPG Galapagos	$80.16M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/23/2025 (Estimated)
GNMSF Genmab A/S	$1.14B	$17.63	11.97	∞	N/A	35.11%	19.23%	15.44%	8/7/2025 (Estimated)
TEVA Teva Pharmaceutical Industries	-$1.64B	-$1.15	N/A	6.37	0.86	-7.74%	45.44%	6.95%	7/30/2025 (Estimated)

Latest GNMSF, ALNY, GLPG, BMRN, and TEVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/23/2025	Q2 2025	GLPG Galapagos	-$0.34	N/A	N/A	N/A	$80.13 million	N/A
5/8/2025	Q1 2025	GNMSF Genmab A/S	$1.88	$3.05	+$1.17	$3.05	$761.09 million	$765.14 million
5/7/2025	Q1 2025	TEVA Teva Pharmaceutical Industries	$0.47	$0.52	+$0.05	$0.18	$3.99 billion	$3.89 billion
5/1/2025	Q1 2025	ALNY Alnylam Pharmaceuticals	-$0.37	-$0.44	-$0.07	-$0.44	$584.32 million	$594.19 million
4/23/2025	Q1 2025	GLPG Galapagos	-$0.23	-$2.47	-$2.24	-$2.45	$72.22 million	$97.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
GLPG Galapagos	N/A	N/A	N/A	N/A	N/A
GNMSF Genmab A/S	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	8.88	3.04	2.98
BMRN BioMarin Pharmaceutical	0.10	5.52	3.49
GLPG Galapagos	N/A	7.95	7.86
GNMSF Genmab A/S	N/A	5.34	5.32
TEVA Teva Pharmaceutical Industries	2.59	1.03	0.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
BMRN BioMarin Pharmaceutical	98.71%
GLPG Galapagos	32.46%
GNMSF Genmab A/S	N/A
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	1.20%
BMRN BioMarin Pharmaceutical	0.85%
GLPG Galapagos	2.91%
GNMSF Genmab A/S	1.54%
TEVA Teva Pharmaceutical Industries	0.55%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,230	130.39 million	128.82 million	Optionable
BMRN BioMarin Pharmaceutical	3,040	191.78 million	190.15 million	Optionable
GLPG Galapagos	1,310	N/A	N/A	Optionable
GNMSF Genmab A/S	2,682	66.07 million	65.06 million	Not Optionable
TEVA Teva Pharmaceutical Industries	36,830	1.15 billion	1.14 billion	Optionable

GNMSF, ALNY, GLPG, BMRN, and TEVA Headlines

Recent News About These Companies

Allspring Global Investments Holdings LLC Purchases 5,186,592 Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

June 29 at 5:32 AM | marketbeat.com

Sequoia Financial Advisors LLC Increases Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

June 29 at 4:14 AM | marketbeat.com

Asset Management One Co. Ltd. Reduces Stock Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

June 29 at 3:44 AM | marketbeat.com

Achmea Investment Management B.V. Sells 122,509 Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

June 28 at 5:26 AM | marketbeat.com

UBS Group Lowers Teva Pharmaceutical Industries (NYSE:TEVA) Price Target to $23.00

June 28 at 2:33 AM | americanbankingnews.com

Teva’s CEO shares ‘Pivot to Growth’ progress

June 27 at 6:41 PM | fiercepharma.comF

Zacks Research Has Optimistic Outlook of TEVA Q1 Earnings

June 27 at 6:39 AM | marketbeat.com

Valorum Biologics to commercialize Formycon’s Eylea Biosimilar FYB203 in US and Canada

June 27 at 4:54 AM | ophthalmologytimes.comO

Teva Releases Q2 2025 Aide Memoire

June 26, 2025 | financialpost.comF

Teva Releases Q2 2025 Aide Memoire

June 26, 2025 | globenewswire.com

Teva Pharmaceutical Industries (NYSE:TEVA) Given New $23.00 Price Target at UBS Group

June 26, 2025 | marketbeat.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Acquired by GHP Investment Advisors Inc.

June 26, 2025 | marketbeat.com

Teva Pharmaceutical Industries Ltd (TEVA) Announces Upcoming Q2 2025 Financial Results Release ...

June 25, 2025 | gurufocus.com

Teva points to long-term efficacy of Ajovy in migraine

June 25, 2025 | thepharmaletter.comT

Teva Pharmaceutical Industries Ltd. to Announce Second Quarter 2025 Financial Results on July 30, 2025

June 25, 2025 | quiverquant.comQ

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

June 25, 2025 | financialpost.comF

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

June 25, 2025 | globenewswire.com

Teva Pharmaceutical Industries Ltd. - Page 2 - The New York Times

June 25, 2025 | nytimes.com

Retirement Systems of Alabama Takes Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

June 25, 2025 | marketbeat.com

Teva Pharmaceutical Industries Ltd: Final Data from Teva's PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY (fremanezumab) for the Prevention of Chronic ...

June 24, 2025 | finanznachrichten.de

Teva Pharmaceutical Industries Presents Final Analysis of PEARL Study Demonstrating Sustained Effectiveness of AJOVY in Migraine Prevention at EAN 2025 Congress - Nasdaq

June 24, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNMSF, ALNY, GLPG, BMRN, and TEVA Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$326.09 +3.26 (+1.01%)

As of 04:00 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

BioMarin Pharmaceutical NASDAQ:BMRN

$54.97 -0.20 (-0.36%)

As of 04:00 PM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Galapagos NASDAQ:GLPG

$27.99 +0.01 (+0.04%)

As of 04:00 PM Eastern

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Genmab A/S OTCMKTS:GNMSF

$211.09 0.00 (0.00%)

As of 06/27/2025

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Teva Pharmaceutical Industries NYSE:TEVA

$16.76 0.00 (0.00%)

As of 03:58 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time